Loading...

BMRN BIOMARIN PHARMACEUTICAL INC Product Launches 8-K Filing

BMRN

BMRN

BIOMARIN PHARMACEUTICAL INC

(BMRN)

2025 8-K

Trial Discontinuation

Financial Results Report

Major Debt Issuance

Debt Offering Announcement

BioMarin Financial Update

Financial Update

Treatment Discontinued

Merger Agreement Announcement

Management Change

Quarterly Earnings Report

Quarterly Financial Update

Financial Statements

Management Changes

Merger of Equals

Financial Statements

Bylaw Amendments

Board Appointment

Q4 Financial Results

Q3 Financial Results

Financial Guidance

Workforce Reduction

Management Change

Earnings Report

Annual Meeting Voting Results

Discontinuation of R&D Prog...

Earnings Reports

Settlement of Stockholder D...

Earnings Reports

Departure of Directors

Cooperation Agreement with ...

Retirement and Appointment

Earnings Reports

Earnings Reports

Annual Meeting Approval

Financial Results Announcement

Earnings Reports

Business Update at J.P. Mor...

External Links:

On December 19, 2025, BioMarin Pharmaceutical Inc. announced it will stop developing BMN 349, a treatment for liver disease related to Alpha-1 antitrypsin deficiency. This is a significant event for the company.

AI Assistant

BIOMARIN PHARMACEUTICAL INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.